Zomedica (NYSEAMERICAN:ZOM) Raised to Strong-Buy at Noble Financial

Noble Financial upgraded shares of Zomedica (NYSEAMERICAN:ZOM) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Zomedica Stock Up 5.6 %

Shares of ZOM stock opened at $0.15 on Monday. Zomedica has a fifty-two week low of $0.12 and a fifty-two week high of $0.23.

Institutional Investors Weigh In On Zomedica

An institutional investor recently raised its position in Zomedica stock. Price T Rowe Associates Inc. MD grew its position in Zomedica Corp. (NYSEAMERICAN:ZOM) by 41.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 948,300 shares of the company’s stock after acquiring an additional 276,100 shares during the period. Price T Rowe Associates Inc. MD owned 0.10% of Zomedica worth $139,000 as of its most recent filing with the SEC. 8.95% of the stock is currently owned by institutional investors and hedge funds.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.